Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-Q _____________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit ...

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 • Cash balance of $302.8 million as of March 31, 2024 • Conference call to provide business updates today, May 8 at 1:30 p.m. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | (S ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Andrew McKibben - Vice President-Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Lili Nsongo - Leerink Partners Brian Skorney - Baird Ed Arce - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you fo ...

• Safety 27 PBC: Most Prevalent Cholestatic Liver Disease *Mirum market research Phase 2b Study of Volixibat in PBC Patients with Cholestatic Pruritus • Topline data to include pruritus, safety, and other secondary endpoints Primary Endpoint • Change in pruritus from Baseline to 28wk • Markers of disease and QoL • Markers of disease progression WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment • Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function whil ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head, R&D Eric Bjerkholt - CFO Conference Call Participants Josh Schimmer - Cantor Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners David Lebowitz - Citigroup Brian Skorney - Robert W. Baird & Co. Ed Arce - H.C. Wainwright Jonathan Wolleben - JMP Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Indicat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83- ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining. I would like to wel ...

Genetic disease leading to bile acid build-up and progressive liver damage 1 in every 50,000 to 100,000 births in the US and Europe This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our pending acquisition of CHOLBAM and CHENODAL and the ...